Is AstraZeneca a Bargain Buy?
AstraZeneca (NASDAQ: AZN) has been an underwhelming stock to own over the past year. Its shares are up less than 2% while the S&P 500 has soared more than 32%.
Part of the lackluster showing is likely due to its COVID-19 vaccine, which has faced some bad press this year, based both on questions about its overall effectiveness and on its potentially causing blood clots. While it's not currently being sold in the U.S., AstraZeneca's vaccine is approved for use in other parts of the world, including the European Union, the U.K., and Canada, and it is possible that the U.S. Food and Drug Administration could approve it later this year.
But AstraZeneca is more than just a COVID stock, and it has plenty of growth opportunities ahead. Could this overlooked stock even be a bargain buy, given how ridiculously overpriced some companies are right now?
Source Fool.com
